1108 related articles for article (PubMed ID: 21159662)
1. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.
Drygin D; Lin A; Bliesath J; Ho CB; O'Brien SE; Proffitt C; Omori M; Haddach M; Schwaebe MK; Siddiqui-Jain A; Streiner N; Quin JE; Sanij E; Bywater MJ; Hannan RD; Ryckman D; Anderes K; Rice WG
Cancer Res; 2011 Feb; 71(4):1418-30. PubMed ID: 21159662
[TBL] [Abstract][Full Text] [Related]
2. The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.
Rebello RJ; Kusnadi E; Cameron DP; Pearson HB; Lesmana A; Devlin JR; Drygin D; Clark AK; Porter L; Pedersen J; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
Clin Cancer Res; 2016 Nov; 22(22):5539-5552. PubMed ID: 27486174
[TBL] [Abstract][Full Text] [Related]
3. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
[TBL] [Abstract][Full Text] [Related]
4. Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer.
Cornelison R; Dobbin ZC; Katre AA; Jeong DH; Zhang Y; Chen D; Petrova Y; Llaneza DC; Steg AD; Parsons L; Schneider DA; Landen CN
Clin Cancer Res; 2017 Nov; 23(21):6529-6540. PubMed ID: 28778862
[No Abstract] [Full Text] [Related]
5. CX-5461-loaded nucleolus-targeting nanoplatform for cancer therapy through induction of pro-death autophagy.
Duo Y; Yang M; Du Z; Feng C; Xing C; Wu Y; Xie Z; Zhang F; Huang L; Zeng X; Chen H
Acta Biomater; 2018 Oct; 79():317-330. PubMed ID: 30172068
[TBL] [Abstract][Full Text] [Related]
6. rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis.
Negi SS; Brown P
Oncotarget; 2015 Jul; 6(20):18094-104. PubMed ID: 26061708
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Targeting of RNA Polymerase I With the Small-Molecule CX-5461 for Prevention of Arterial Injury-Induced Neointimal Hyperplasia.
Ye Q; Pang S; Zhang W; Guo X; Wang J; Zhang Y; Liu Y; Wu X; Jiang F
Arterioscler Thromb Vasc Biol; 2017 Mar; 37(3):476-484. PubMed ID: 28062495
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling.
Quin J; Chan KT; Devlin JR; Cameron DP; Diesch J; Cullinane C; Ahern J; Khot A; Hein N; George AJ; Hannan KM; Poortinga G; Sheppard KE; Khanna KK; Johnstone RW; Drygin D; McArthur GA; Pearson RB; Sanij E; Hannan RD
Oncotarget; 2016 Aug; 7(31):49800-49818. PubMed ID: 27391441
[TBL] [Abstract][Full Text] [Related]
9. First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.
Khot A; Brajanovski N; Cameron DP; Hein N; Maclachlan KH; Sanij E; Lim J; Soong J; Link E; Blombery P; Thompson ER; Fellowes A; Sheppard KE; McArthur GA; Pearson RB; Hannan RD; Poortinga G; Harrison SJ
Cancer Discov; 2019 Aug; 9(8):1036-1049. PubMed ID: 31092402
[TBL] [Abstract][Full Text] [Related]
10. PICT-1 triggers a pro-death autophagy through inhibiting rRNA transcription and AKT/mTOR/p70S6K signaling pathway.
Chen H; Duo Y; Hu B; Wang Z; Zhang F; Tsai H; Zhang J; Zhou L; Wang L; Wang X; Huang L
Oncotarget; 2016 Nov; 7(48):78747-78763. PubMed ID: 27729611
[TBL] [Abstract][Full Text] [Related]
11. The rRNA synthesis inhibitor CX-5461 may induce autophagy that inhibits anticancer drug-induced cell damage to leukemia cells.
Okamoto S; Miyano K; Kajikawa M; Yamauchi A; Kuribayashi F
Biosci Biotechnol Biochem; 2020 Nov; 84(11):2319-2326. PubMed ID: 32799625
[TBL] [Abstract][Full Text] [Related]
12. CX-5461 inhibits RNA Pol I in blood cancers.
Cancer Discov; 2014 Dec; 4(12):OF5. PubMed ID: 25477122
[TBL] [Abstract][Full Text] [Related]
13. Effective targeting of RNA polymerase I in treatment-resistant prostate cancer.
Low JY; Sirajuddin P; Moubarek M; Agarwal S; Rege A; Guner G; Liu H; Yang Z; De Marzo AM; Bieberich C; Laiho M
Prostate; 2019 Dec; 79(16):1837-1851. PubMed ID: 31524299
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Bywater MJ; Poortinga G; Sanij E; Hein N; Peck A; Cullinane C; Wall M; Cluse L; Drygin D; Anderes K; Huser N; Proffitt C; Bliesath J; Haddach M; Schwaebe MK; Ryckman DM; Rice WG; Schmitt C; Lowe SW; Johnstone RW; Pearson RB; McArthur GA; Hannan RD
Cancer Cell; 2012 Jul; 22(1):51-65. PubMed ID: 22789538
[TBL] [Abstract][Full Text] [Related]
15. Combined inhibition of RNA polymerase I and mTORC1/2 synergize to combat oral squamous cell carcinoma.
Shi S; Luo H; Wang L; Li H; Liang Y; Xia J; Wang Z; Cheng B; Huang L; Liao G; Xu B
Biomed Pharmacother; 2021 Jan; 133():110906. PubMed ID: 33190037
[TBL] [Abstract][Full Text] [Related]
16. Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis.
Drygin D; Siddiqui-Jain A; O'Brien S; Schwaebe M; Lin A; Bliesath J; Ho CB; Proffitt C; Trent K; Whitten JP; Lim JK; Von Hoff D; Anderes K; Rice WG
Cancer Res; 2009 Oct; 69(19):7653-61. PubMed ID: 19738048
[TBL] [Abstract][Full Text] [Related]
17. Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor.
Leung AWY; Anantha M; Dragowska WH; Wehbe M; Bally MB
J Control Release; 2018 Sep; 286():1-9. PubMed ID: 30016731
[TBL] [Abstract][Full Text] [Related]
18. Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.
Lawrence MG; Obinata D; Sandhu S; Selth LA; Wong SQ; Porter LH; Lister N; Pook D; Pezaro CJ; Goode DL; Rebello RJ; Clark AK; Papargiris M; Van Gramberg J; Hanson AR; Banks P; Wang H; Niranjan B; Keerthikumar S; Hedwards S; Huglo A; Yang R; Henzler C; Li Y; Lopez-Campos F; Castro E; Toivanen R; Azad A; Bolton D; Goad J; Grummet J; Harewood L; Kourambas J; Lawrentschuk N; Moon D; Murphy DG; Sengupta S; Snow R; Thorne H; Mitchell C; Pedersen J; Clouston D; Norden S; Ryan A; Dehm SM; Tilley WD; Pearson RB; Hannan RD; Frydenberg M; Furic L; Taylor RA; Risbridger GP
Eur Urol; 2018 Nov; 74(5):562-572. PubMed ID: 30049486
[TBL] [Abstract][Full Text] [Related]
19. The Selective RNA Polymerase I Inhibitor CX-5461 Mitigates Neointimal Remodeling in a Modified Model of Rat Aortic Transplantation.
Dai C; Sun M; Wang F; Zhu J; Wei Y; Guo X; Ma S; Dong B; Wang G; Jiang F; Wang J
Transplantation; 2018 Oct; 102(10):1674-1683. PubMed ID: 30247451
[TBL] [Abstract][Full Text] [Related]
20. CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer.
Sanij E; Hannan KM; Xuan J; Yan S; Ahern JE; Trigos AS; Brajanovski N; Son J; Chan KT; Kondrashova O; Lieschke E; Wakefield MJ; Frank D; Ellis S; Cullinane C; Kang J; Poortinga G; Nag P; Deans AJ; Khanna KK; Mileshkin L; McArthur GA; Soong J; Berns EMJJ; Hannan RD; Scott CL; Sheppard KE; Pearson RB
Nat Commun; 2020 May; 11(1):2641. PubMed ID: 32457376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
